Chemotherapy Toxicity Profile in Adjuvant Treated Colorectal Carcinoma Patients  

作　　者：Nagy Samy Gobran Mohammed Reda Kelany Mohammed Abdallah Fathy 

机构地区：[1]Clinical Oncology & Nuclear Medicine Department, Ain Shams University, Cairo, Egypt

出　　处：《Journal of Cancer Therapy》2020年第2期74-87,共14页癌症治疗（英文）

摘　　要：Background:?Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer-related deaths in the world. The treatment of stage III CRC consists of surgery followed by adjuvant chemotherapy with either single agent capecitabine or combination therapy consisting of FOLFOX?or XELOX, all of which have been shown to be effective in improving disease-free survival (DFS) and overall survival (OS). However, toxicities acquired from chemotherapy can affect a cancer patient’s quality of life and result in early?treatment discontinuation. Common toxicities include hematological, gastrointestinal (GI), constitutional, dermatological, and neurological.?Aim of the Work: The present work was aimed to assess and evaluate chemotherapy toxicities in adjuvant treatment in CRC patients and analyze certain factors that might increase chemotherapy toxicity. Patients and Methods: This is retrospective study included a total of 72 patients of colorectal carcinoma received adjuvant chemotherapy at Clinical Oncology Department, Ain Shams University. The study was conducted between Jan. 2012 and Jan. 2017. Results: We found that?the most chemotherapy reported was neurological toxicity in (73.6%), gastrointestinal symptoms (diarrhea 52.7%, nausea 30.6%, vomiting 27.8% & oral mucositis 24%), hematological toxicity (neutropenia 40.3%, anemia 34.7%, thrombocytopenia 12.5%), fatigue 20.9%, hepatic toxicity 18.1%, dermatological toxicity 9.7% & renal toxicity 5.6%). older patients have significant incidence of neurological toxicity (p-value?= 0.023) and fatigue (p-value?= 0.038). females have significant incidence of anemia (p-value = 0.017). increase of oxaliplatin?cumulative dose increase incidence of neurological toxicity (p-value?= 0.024), thrombocytopenia (p-value?= 0.007) and renal toxicity (p-value?= 0.030). Oxaliplatin containing regimens have high significant correlation with neurological toxicity (p-value = 0.000) and capcitabine has high significant correlation with dermatological toxicity (p-value = Background:?Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer-related deaths in the world. The treatment of stage III CRC consists of surgery followed by adjuvant chemotherapy with either single agent capecitabine or combination therapy consisting of FOLFOX?or XELOX, all of which have been shown to be effective in improving disease-free survival (DFS) and overall survival (OS). However, toxicities acquired from chemotherapy can affect a cancer patient’s quality of life and result in early?treatment discontinuation. Common toxicities include hematological, gastrointestinal (GI), constitutional, dermatological, and neurological.?Aim of the Work: The present work was aimed to assess and evaluate chemotherapy toxicities in adjuvant treatment in CRC patients and analyze certain factors that might increase chemotherapy toxicity. Patients and Methods: This is retrospective study included a total of 72 patients of colorectal carcinoma received adjuvant chemotherapy at Clinical Oncology Department, Ain Shams University. The study was conducted between Jan. 2012 and Jan. 2017. Results: We found that?the most chemotherapy reported was neurological toxicity in (73.6%), gastrointestinal symptoms (diarrhea 52.7%, nausea 30.6%, vomiting 27.8% & oral mucositis 24%), hematological toxicity (neutropenia 40.3%, anemia 34.7%, thrombocytopenia 12.5%), fatigue 20.9%, hepatic toxicity 18.1%, dermatological toxicity 9.7% & renal toxicity 5.6%). older patients have significant incidence of neurological toxicity (p-value?= 0.023) and fatigue (p-value?= 0.038). females have significant incidence of anemia (p-value = 0.017). increase of oxaliplatin?cumulative dose increase incidence of neurological toxicity (p-value?= 0.024), thrombocytopenia (p-value?= 0.007) and renal toxicity (p-value?= 0.030). Oxaliplatin containing regimens have high significant correlation with neurological toxicity (p-value = 0.000) and capcitabine has high significant correlation with dermatological toxicity (p-value =

关 键 词：CHEMOTHERAPY TOXICITY ADJUVANT CHEMOTHERAPY CRC 

分 类 号：R73[医药卫生—肿瘤]